BNP Paribas Financial Markets Purchases Shares of 2,251 Septerna, Inc. (NASDAQ:SEPN)

BNP Paribas Financial Markets purchased a new stake in shares of Septerna, Inc. (NASDAQ:SEPN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,251 shares of the company’s stock, valued at approximately $52,000.

Several other hedge funds have also added to or reduced their stakes in SEPN. JPMorgan Chase & Co. bought a new position in Septerna during the 4th quarter worth $871,000. Jane Street Group LLC bought a new position in Septerna during the 4th quarter worth $600,000. MetLife Investment Management LLC bought a new position in shares of Septerna in the fourth quarter worth $265,000. Barclays PLC bought a new position in shares of Septerna in the fourth quarter worth $659,000. Finally, TRV GP VI LLC bought a new position in shares of Septerna in the fourth quarter worth $72,191,000.

Analysts Set New Price Targets

SEPN has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised their price target on Septerna from $20.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, May 16th. Wells Fargo & Company lifted their target price on Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 16th.

Septerna Stock Up 0.4%

Septerna stock opened at $9.97 on Wednesday. The stock’s 50 day moving average is $7.22 and its 200 day moving average is $13.04. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter. On average, equities research analysts forecast that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other Septerna news, Director Alan Ezekowitz bought 41,355 shares of the stock in a transaction on Thursday, March 6th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the acquisition, the director now owns 104,101 shares in the company, valued at $624,606. This trade represents a 65.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 4.30% of the stock is currently owned by corporate insiders.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.